Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 3, 2006, Pages 252-259

  Saxena, Kirti ^a   Howe, Meghan ^a   Simeonova, Diana ^a   Steiner, Hans ^a   Chang, Kiki ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; MOOD STABILIZER; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; AGE; AGGRESSION; ARTICLE; BIPOLAR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYCLOTHYMIA; DRUG EFFICACY; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; MALE; OPEN STUDY; OPPOSITIONAL DEFIANT DISORDER; OVERT AGGRESSION SCALE; PSYCHOPHARMACOLOGY; RATING SCALE;

ADOLESCENT; AFFECT; AGGRESSION; ANTIMANIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; CHILD; CYCLOTHYMIC DISORDER; DEPRESSIVE DISORDER, MAJOR; DYSTHYMIC DISORDER; FEMALE; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MALE; RISK FACTORS; VALPROIC ACID;

EID: 33745173804     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.252     Document Type: Article

References (34)

1. Achenbach TM: Manual for Youth Self-Report and 1991 Profile. Burlington (Vermont), University of Vermont Department of Psychiatry, 1991.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
3. Barratt ES, Stanford MS, Kent TA, Felthous A: Neuropsychological and cognitive psychophysiological substrates of impulsive aggression. Biol Psychiatry 41:1045-1061, 1997.
4. Bjork JM, Moeller FG, Kramer GL, Kram M, Suris A, Rush AJ, Petty F: Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 101:131-136, 2001.
5. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, et al: Efficacy of divalproex versus lithium and placebo in the treatment of mania: The Depakote Mania Study Group. JAMA 271:918-924, 1994.
6. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr, Chou JC, Keck PE, Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ: A randomized, placebo-controlled, 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: Divalproex Maintenance Study Group. Arch Gen Psychiatry 57:481-489, 2000.
7. Brown GL, Linnoila MI: CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiatry 51:31-41, 1990.
8. Chang KD, Adleman N, Dienes K, Reiss AL, Ketter TA: Bipolar offspring: A window into bipolar disorder evolution. Biol Psychiatry 53:945-941, 2003a.
9. Chang K, Dienes K, Blasey C, Adelman N, Ketter T, Steiner H: Divalproex in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J Clin Psychiatry 64:936-942, 2003b.
10. Coccaro EF, Harvey PD, Kupsaw LE, Herbert JL, Bernstein DP: Overt Aggression Scale-Modified (OAS-M). In: American Psychiatric Association Task Force for the Handbook of Psychiatric Measures. Washington (DC), American Psychiatric Association, 2000, pp 699-702.
11. Dienes KA, Chang KD, Blasey CM, Adleman NE, Steiner H: Characterization of children of bipolar parents by parent report CBCL. J Psychiatr Res 36:337-345, 2002.
12. Donovan SJ, Susser ES, Nunes EV, Stewart JW, Quitkin FM, Klein DF: Divalproex treatment of disruptive adolescents: A report of 10 cases. J Clin Psychiatry 58:12-15, 1997.
13. Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W, Susser E, Klein DF: Divalproex treatment for youth with explosive temper and mood liability: A double blind, placebo-controlled, crossover design. Am J Psychiatry 157:818-820, 2000.
14. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington (DC), American Psychiatric Press, Inc., 1995.
15. Geller B, Williams M, Zimerman B, Frazier J: Washington University in St. Louis, Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS). St Louis, (Missouri), Washington University, 1996.
16. Geller BG, Warner K, Williams M, et al: Prepubertal and young adolescent bipolarity versus ADHD: Assessment and validity using the WASH-U-KSADS, CBCL, and TRF. J Affect Disord 51:93-100, 1998.
17. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 12:56-62, 1960.
18. Johannessen CU, Johannessen SI: Valproate: Past, present, and future: CNS Drug Rev 9:199-216, 2003.
19. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, Emslie GJ, Weinberg WA, Rush AJ: Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 39:713-720, 2000.
20. Loscher W: Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31-59, 1999.
21. Loscher W: Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16:669-694, 2002.
22. Lujan R, Shigemoto R, Lopez-Bendito G: Glutamate and GABA receptor signalling in the developing brain. Neuroscience 130:567-580, 2005.
23. Malone RP, Sheikh R, Zito JM: Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 50:171-174, 1999.
24. Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M: A double-blind, placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649-654, 2000.
25. Mick E, Biederman J, Mick E, Biederman J, Pandina G, Faraone SV: A preliminary meta-analysis of child behavior checklist in pediatric bipolar disorder. Biol Psychiatry 53:1021-1027, 2003.
26. Pavuluri MN, Henry DB, Carbray JA, Naylor MW, Janicak PG: Divalproex sodium for pediatric mixed mania: A 6-month prospective trial. Bipolar Disord 7:266-273, 2005.
27. Petroff OA, Rothman DL, Behar KL, Hyder F, Mattson RH: Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 8:120-127, 1999.
28. Presser J, Hughes CW, Sheikha S, Kowatch RA, Kramer GL, Rosenbarger N, Trent J, Petty F: Plasma GABA in children and adolescents with mood, behavior, and comorbid mood and behavior disorders: A preliminary study. J Child Adolesc Psychopharmacol 7:181-199, 1997.
29. Steiner H: The evaluation and management of aggression in juveniles. New Dir Psychiatry 22:355-369, 2002.
30. Steiner H, Petersen ML, Saxena K, Ford S, Matthews Z: Divalproex sodium for the treatment of conduct disorder: A randomized, controlled clinical trial. J Clin Psychiatry 64:1183-1191, 2003.
31. Steiner H, Saxena K, Chang K: Psychopharmacological strategies for the treatment of aggression in youth. CNS Spectr 8:298-308, 2003.
32. Swann AC, Bjorn JM, Moeller FG, Dougherty DM: Two models of impulsivity: Relationship to personality traits and psychopathology. Biol Psychiatry 51:988-994, 2002.
33. Wagner KD, Weller EB, Carlson GA, Sachs G, Biederman J, Frazier JA, Wozniak P, Tracy K, Weller RA, Bowden C: An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 41:1224-1230, 2002.
34. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 133:429-135, 1978.